Articles
WHO issues global guideline on the use of GLP-1 medicines in treating obesity
The WHO has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.
Obesity affects people in every country and was associated with 3.7 million deaths worldwide in 2024. Without decisive action, the number of people with obesity is projected to double by 2030.
Click here to access the article.